CD276 and squamous cell lung carcinoma: In line with previous reports, we consistently observed B7-H3–high tumors to be depleted in CD8+ T cells, including in triple-negative breast cancers (1.2% vs. 1.9%, q < 0.0001), lung squamous cell carcinomas (1.0% vs. 1.7%, q < 0.0001), and lung adenocarcinomas (1.4% vs. 1.9%, q < 0.0001; Fig. 4A; refs. 29, 30).